NCT05482607 Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease
| NCT ID | NCT05482607 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Hospital, Nancy, France |
| Condition | Systemic Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2025-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-01-01 with a primary completion date of 2025-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. Interstitial lung disease (ILD) concerns almost 50 % of SSc patients and represents the main cause of mortality. SSc-ILD is variable: from limited forms (with asymptomatic patients) to extensive lesions. Disease course in SSc-ILD is also highly variable: patients can experience stable disease, slow or fast progression. Investigators performed unsupervised clustering analysis to classify SSc-ILD according to elementary radiological lesions on HRCT scan.
Eligibility Criteria
Inclusion Criteria: * Patients with systemic sclerosis according to 2013 ACR/EULAR criteria * Patients with interstitial lung disease on HRCT chest Exclusion Criteria: * Patients with an alternative diagnosis of SSc-associated ILD (silicosis, sarcoidosis, lung cancer or other significant lung abnormalities)
Contact & Investigator
Paul Decker, MD
PRINCIPAL INVESTIGATOR
Central Hospital, Nancy, France
Frequently Asked Questions
Who can join the NCT05482607 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Systemic Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05482607 currently recruiting?
Yes, NCT05482607 is actively recruiting participants. Contact the research team at p.decker@chru-nancy.fr for enrollment information.
Where is the NCT05482607 trial being conducted?
This trial is being conducted at Nancy, France.
Who is sponsoring the NCT05482607 clinical trial?
NCT05482607 is sponsored by Central Hospital, Nancy, France. The principal investigator is Paul Decker, MD at Central Hospital, Nancy, France. The trial plans to enroll 100 participants.